You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Drug Sales Trends for GEMFIBROZIL

✉ Email this page to a colleague

« Back to Dashboard

Payment Methods and Pharmacy Types for GEMFIBROZIL (2021)

Revenues by Pharmacy Type

Chart
Table

Pharmacy Type	Revenues
MAIL-ORDER	$17,289,313
INSIDE ANOTHER STORE	$16,497,146
[disabled in preview]	$28,811,769
This preview shows a limited data set Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Chart
Table

Pharmacy Type	Units
MAIL-ORDER	458,701
INSIDE ANOTHER STORE	879,572
[disabled in preview]	1,453,434
This preview shows a limited data set Subscribe for full access, or try a Trial

Revenues by Payment Method

Chart
Table

Payment Method	Revenues
MEDICAID	$7,531,497
MEDICARE	$14,030,380
[disabled in preview]	$41,036,351
This preview shows a limited data set Subscribe for full access, or try a Trial

Drug Sales Revenue Trends for GEMFIBROZIL

Drug Units Sold Trends for GEMFIBROZIL

Annual Sales Revenues and Units Sold for GEMFIBROZIL

These sales figures are drawn from a US national survey of drug expenditures

Subscribe to access the full database, or Subscribe
Drug Name	Revenues (USD)	Units	Year
GEMFIBROZIL	⤷ Subscribe	⤷ Subscribe	2021
GEMFIBROZIL	⤷ Subscribe	⤷ Subscribe	2020
GEMFIBROZIL	⤷ Subscribe	⤷ Subscribe	2019
>Drug Name	>Revenues (USD)	>Units	>Year

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.